Meeting
2021 ASCO Annual Meeting
TP53 and CHEK2 germline mutations in malignant solid tumors.
Authors
Zhiye Zhang
The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, China
Zhiye Zhang , Yaqing Wu , Ningning Luo , Qin Zhang , Tiantian Han , Xuesong Bu , Qin Shuai , Yingxue Qi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 3119)
DOI
10.1200/JCO.2021.39.15_suppl.3119
Abstract #
3119
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Clinical outcomes of immune checkpoint inhibitor treatment in patients with classic cold tumors identified to have a high tumor mutational burden via ctDNA.
First Author: Reagan Barnett
Poster
2015 ASCO Annual Meeting
Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.
First Author: Sarina Anne Piha-Paul
Poster
2023 ASCO Annual Meeting
Distributional range of tumor mutational burden (TMB) across multiple cancer types emphasizing the importance of different cutoff values in different tumor types for clinical interpretation: A consensus statement from the SEQUOIA consortium.
First Author: Wojciech Swat
Poster
2023 ASCO Annual Meeting
Utility of multi-gene panel-based germline analysis following genomic profiling and cascade testing in advanced solid tumors: An initial report of the BRANCH study.
First Author: Takeshi Kuwata